| Document |
Document Title |
|
WO/2012/097876A1 |
A novel class of cell-penetrating enhancers with unusual chemical structure is herein disclosed. Said cell-penetrating enhancers are non-linear and non peptidic (guanidyl)-oligosaccharidic derivatives, which can be easily obtained accord...
|
|
WO/2012/099477A1 |
The invention relates to methods of localising biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S' for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to ...
|
|
WO/2012/097454A1 |
This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof: wherein R1 to R4. R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said c...
|
|
WO/2012/099904A1 |
The present invention provides novel methods for determining the presence or amount of a hydrolytic enzyme in a sample, based on novel substrates for the enzymes, and also provides compositions and methods that provide highly sensitive a...
|
|
WO/2012/094752A1 |
A process for producing a natural sweetening enhancer composition comprising at least an Rebaudioside C (RC) extract, said process comprises the steps of preparing a saccharide mother liquor comprising an RC mass content of at least 15%;...
|
|
WO/2012/096884A1 |
Provided are phenethyl isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.
|
|
WO/2012/093091A2 |
The present invention relates to saccharide mimics which show a better biological activity at low concentrations as known saccharide mimics in inhibiting angiogenesis and inhibiting formation of metastasis by inhibiting adhesion and/or m...
|
|
WO/2012/094540A2 |
Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are pr...
|
|
WO/2012/091570A1 |
A carbohydrate-containing feedstock is converted in a process, which process comprises contacting the feedstock in a first step with an alcohol in the presence of a first acid catalyst at a temperature below 100 °C to yield an intermedi...
|
|
WO/2012/088598A1 |
A process for producing the natural sweetener composition which comprises at least one of steviolbioside (STB) extract, Rebaudioside B extract and Rebaudioside D extract ("collectively, the "extracts") comprises the steps of preparing a ...
|
|
WO/2012/088612A1 |
A method for breeding Stevia rebaudiana with a high content of RA comprises selecting the plants in the perfect stage with a high RA content as parents and hybridizing them to produce F1 generation seeds; stabilizing the traits of the F1...
|
|
WO/2012/088593A1 |
Natural steviol glycosides sweetener compositions comprise a blend of Rebaudioside C extract and at least one of Rebaudioside A extract and STV extract including methods for producing the same and uses thereof in foods, beverages, functi...
|
|
WO/2012/088264A2 |
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ colum...
|
|
WO/2012/086811A1 |
The present invention provides a food intake suppressant and an anti-obesity agent containing the compounds represented by formula (I''). (In the formula, at least one of R11, R12, R13, R14 and R15 is a G-O- group (where G represents a s...
|
|
WO/2012/086812A1 |
The present invention provides the compounds represented by formula (I''), a method for producing the compounds, and GLP-1 secretagogues etc. containing the compounds. (In the formula, at least one of R11, R12, R13, R14 and R15 is a G-O-...
|
|
WO/2012/082677A1 |
Sweetener compositions comprising particular glycoside blends are described in this paper. The glycioside blends comprise rebaudioside A, rebaudioside B, and/or rebaudioside D in various proportions. The sweetener composition can also in...
|
|
WO/2012/082493A1 |
A process for production of crystalline rebaudioside B from rebaudioside A is described. Additionally, four distinct crystal polymorphic forms of rebaudioside B are described, as well as methods for converting from one crystal polymorphi...
|
|
WO/2012/082650A2 |
The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present...
|
|
WO/2012/079039A1 |
A preparation of antibiotic G418 with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic G418 with a purity of greater than 95% and no individual group ...
|
|
WO/2012/073214A2 |
Compounds having the general formula (I) and their biological applications.
|
|
WO/2012/071371A2 |
The disclosure relates to labeling glycans and glycosphingolipids from undefined mixtures with chemical moieties that emit light when exposed to electromagnetic radiation and uses of these labeled glycans and glycosphingolipids in microa...
|
|
WO/2012/069730A1 |
The invention relates to a compound having Formula (I), nC7-H15-O-(G)p-H (I), where G is the residue of a reducing sugar, and p is a decimal number greater than or equal to 1.05 and less than or equal to 5. The invention also relates to ...
|
|
WO/2012/071508A1 |
A method of preparing a ribofuranose derivative essentially free of pyranose compounds includes a step of contacting a solution of MDR containing MDRP as an impurity in a solvent including methanol and/or tetrahydrofuran with at least on...
|
|
WO/2012/066949A1 |
Radish is a plant highly valuable as a food material. The purpose of the present invention is to provide a glucoraphanin-rich radish plant at a low cost using neither a chemical treatment nor a transgenic treatment, said glucoraphanin ha...
|
|
WO/2012/068457A1 |
The invention relates to the use of adsorb/desorb chromatography to prepare enriched compositions comprising rebaudioside B and/or rebaudioside D. Compositions with enriched rebaudioside-B and/or rebaudioside-D components may be prepared...
|
|
WO/2012/067978A1 |
Compounds having antibacterial activity are disclosed. The compounds have a structure including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with prepa...
|
|
WO/2012/006742A9 |
A simple extraction method for preparing an organic certifiable stevia extract with high sweetness and optionally with antioxidant properties is provided. The extraction method involves extraction of stevia leaves that have been dried an...
|
|
WO/2012/062996A1 |
The invention relates to compounds of formula (I) where: R1 ≠ 2-deoxystreptamine and the derivatives thereof substituted in positions 5 and/or 6; R2 and R6 are the same or different and represent a primary, secondary or tertiary amine ...
|
|
WO/2012/065054A1 |
A compound, or a pharmaceutically acceptable salt, ester, hydrate or solvate thereof, comprising formula I: A-B wherein A comprises a carbohydrate that is a neuraminidase or galactosidase substrate; B comprises an odorant moiety; B is co...
|
|
WO/2012/055010A1 |
The present document describes a neutraceutical, cosmeceuticals, functional food, pharmaceutical, food ingredient, and non-food ingredient compositions comprising sugar maple extract, essential oil compositions comprising oil extracted f...
|
|
WO/2012/052596A1 |
The invention relates to novel inhibitors of tumour cell division. These inhibitors are semi-synthetic derivatives of neurostatin. The invention also relates to a novel method for the synthesis of the inhibitors and neurostatin. In addit...
|
|
WO/2012/052843A1 |
The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharamceutical composition comprising the p...
|
|
WO/2012/049437A2 |
The invention relates to a method for transforming iota-carrageenan into alpha-carrageenan by means of a new class of 4S-iota-carrageenan sulfatase. The invention also relates to carrageenans obtained by said conversion method. The inven...
|
|
WO/2011/044501A9 |
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defin...
|
|
WO/2012/048119A2 |
The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent ...
|
|
WO/2012/047763A2 |
Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.
|
|
WO/2012/045363A1 |
There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, ...
|
|
WO/2012/042508A1 |
A commercially viable method is provided herein for isolating and purifying steviol glycosides from a source containing said steviol glycosides The method includes the first step of passing an organic solution containing said steviol gly...
|
|
WO/2012/037034A1 |
Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E- selectin anta...
|
|
WO/2012/021981A1 |
The present invention describes phytochemicals present in maple syrup and maple tree extracts by butanol, ethyl acetate and methanol. Novel compounds are isolated from maple syrups, including one compound Quebecol generated in the maple ...
|
|
WO/2011/044502A9 |
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. ...
|
|
WO/2012/017199A1 |
Compounds of Formula (1) isolated from Bacillus spp. that act as colouring agents and/or antioxidants for use in foodstuffs and animal feed, wherein X is independently selected from methyl and COOR wherein R is independently selected fro...
|
|
WO/2011/044498A9 |
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...
|
|
WO/2011/044503A9 |
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 ...
|
|
WO/2012/016994A1 |
The present invention relates to novel bisphosphonate duplex drugs, methods for preparing said compound; pharmaceutical compositions containing the same; as well as the use of said compounds in human and veterinary medicine, and, in part...
|
|
WO/2012/012339A2 |
The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs of the analgesic acetaminophen. This invention relates to a method for the production of a broad group of glycosides of ...
|
|
WO/2011/044538A9 |
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are...
|
|
WO/2011/153815A1 |
N-acyl modified sialic acid (α-(2→6)-D-aminopyranose derivatives, their synthesis methods and uses are disclosed. Sialic acid (α-(2→6)-D-aminopyranose derivatives represented by formula (I) are synthesized by using D-aminogalactose...
|
|
WO/2011/154452A1 |
New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceuti...
|
|
WO/2011/155687A1 |
The present invention provides a novel glycolipid derivative compound, a composition for inhibiting vascular smooth muscle cell proliferation using the same and a composition a hyper-proliferative disease of vascular smooth muscle cells ...
|
